<DOC>
	<DOCNO>NCT01269021</DOCNO>
	<brief_summary>In order treat proliferative IgA Nephropathy ( IgAN ) , The investigator design open , prospective , randomize parallel study access efficacy safety MMF compare corticosteroid . Patients fulfill inclusion criterion randomize 1:1 ratio either MMF group corticosteroid group .</brief_summary>
	<brief_title>An Multi-site Prospective Study Assess Efficacy Safety MMF Treatment Proliferative IgA Nephropathy ( IgAN )</brief_title>
	<detailed_description>To access efficacy safety MMF compare corticosteroid treatment proliferative IgA Nephropathy ( IgAN ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Patients sign write informed consent form 2. age 1860 year , female male 3. diagnosed IgA Nephropathy ( IgAN ) renal biopsy 1 month 4. renal biopsy : 10 % &lt; crescent &lt; 50 % ; endocapillary hypercellularity ; necrosis , interstitial fibrosis &lt; 50 % , 5. proteinuria &gt; 1g/24h two time 1. secondary IgA Nephropathy ( IgAN ) ; 2 . eGFR &lt; 30ml/min/1.73m2 . ( MDRD formula ) 3. liver disfunction ; 4. uncontrolled hypertension 5 . WBC &lt; 3000/mm3 6 . Severe viral infection ( HBV , HCV , CMV ) within 3 month ofor know HIV infection . 7. diabetes obesity ( BMI &gt; 28 ) ; 8. severe infection central nervous system symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MMF treatment IgA Nephropathy ( IgAN )</keyword>
</DOC>